BMXMF (BioMerieux) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 08, 2026)


BMXMF BioMerieux SA BMXMF
67 GF Score
Price $82.78
GF Value $127.91
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

BioMerieux's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BMXMF vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, BioMerieux's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMerieux Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where BioMerieux's Margin of Safety % (DCF Earnings Based) falls into.


BMXMF
67GF Score
BioMerieux SA BMXMF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioMerieux (BMXMF) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of $82.78 is trading 35.3% below its estimated GF Value™ of $127.91. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for BMXMF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $127.91 vs. price of $82.78 (35.3% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BMXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
67GF Score

Get the complete analysis for BMXMF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.78
Price
$127.91
GF Value